Featured Research

from universities, journals, and other organizations

Early Drug Therapy For Recently Infected HIV Patients

Date:
September 17, 2001
Source:
Rush Presbyterian St. Luke's Medical Center
Summary:
A novel approach to HIV treatment using a high potency, three-drug combination treatment given in the earliest stages of HIV infection may preserve or enhance a patient’s immunity against HIV, according to doctors at Rush Presbyterian-St. Luke’s Medical Center and Northwestern University Medical School, Chicago.

A novel approach to HIV treatment using a high potency, three-drug combination treatment given in the earliest stages of HIV infection may preserve or enhance a patient’s immunity against HIV, according to doctors at Rush Presbyterian-St. Luke’s Medical Center and Northwestern University Medical School, Chicago.

Researchers are enrolling patients in the clinical trial which looks at the safety and tolerability of the three-drug treatment, and to see at what "rate" the study subjects achieve undetectable levels of HIV-1 (or complete suppression or replications) in their plasma by serial testing several times throughout the study. Doctors believe that early intervention can preserve immune function, lessen risk of viral transmission, reduce the rate of disease progression and viral mutations, decrease the severity of acute disease, and suppress the initial burst of viral replication and dissemination in the body.

Current guidelines for HIV treatment have patients begin antiretroviral therapy when their CD4+T cell count falls below 350. It may take years before HIV-infected patients get to this stage, according to Dr. Harold Kessler, associate director of Infectious Diseases at Rush, and Dr. Frank Palella, assistant professor of medicine and associate director of the HIV Outpatient Center at Northwestern University Medical School. Kessler and Palella are co-principal investigators on the study.

Patients in the 52 week research study will receive a combination of didanosine, stavudine, and an experimental protease inhibitor. "In this three-drug regimen, two of the medications (didanosine and the protease inhibitor) are taken once a day and stavudine is taken twice a day," says Kessler. "It is a highly potent, very compact regimen, and fewer pills make it easier for the patient."

Patients in the study will receive laboratory evaluations to determine the benefit of this early therapy and its effect on the immune system.

"here is a difference between the two groups of early infected HIV patients we are recruiting," says Kessler. "The very early, acute primary stage of HIV infection is when the virus is detected within six to eight weeks of infection, before the body has developed an antibody response to the infection. HIV would go undiagnosed with just an antibody test. A person may be experiencing flu-like symptoms and may go to the doctor and be misdiagnosed with a viral infection such as influenza, mononucleosis or German measles. And then the symptoms may disappear within a few days to a week."

Those patients in the early stage of HIV may have had an HIV test within the last six months to a year, with a negative result. Yet, when they are re-tested and have a positive result, they may have been infected with the virus up to 140 to 150 days earlier. When trying to identify this group of patients, doctors must undertake an assessment of an individual patient’s risk for HIV infection by asking important questions, including those about sexual activity and intravenous drug use. Patients can participate in the trial and choose not to take the antiretroviral therapy medication, and be followed as an untreated group. "We will follow these patients with early HIV infection and have them undergo the same intensive clinical evaluation and testing as those receiving medication," says Palella. In the past, patients were diagnosed with the disease and monitored. Once their counts fell to a certain level, they began treatment, sometimes years later. In this study, patients begin drug therapy as early as within 7 to 14 days of screening.

According to an earlier study using this approach, preliminary data suggest that treatment of primary HIV infection with combination therapy may have a beneficial effect on laboratory indicators of disease progression as well as clinical outcomes.

As a result, the National Institute of Allergy and Infectious Diseases has set up collaborative sites to study various aspects of the treatment of acute and early HIV infection. Three cities and four sites have been selected: Rush and Northwestern in Chicago, the AIDS Research Consortium, Atlanta and the University of Colorado, Denver.

Kessler believes "Based on what we already know from preliminary studies, greater efforts to identify people at a much earlier stage of HIV infection will have a major impact in the fight against HIV and other infectious diseases."

Patients or doctors wanting to enroll in the study should contact Rush study coordinator Elke Narkiewicz 312-942-5000 ext. 29156, or Northwestern study coordinator Baiba Berzins 312-695-5012


Story Source:

The above story is based on materials provided by Rush Presbyterian St. Luke's Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Rush Presbyterian St. Luke's Medical Center. "Early Drug Therapy For Recently Infected HIV Patients." ScienceDaily. ScienceDaily, 17 September 2001. <www.sciencedaily.com/releases/2001/09/010913074042.htm>.
Rush Presbyterian St. Luke's Medical Center. (2001, September 17). Early Drug Therapy For Recently Infected HIV Patients. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2001/09/010913074042.htm
Rush Presbyterian St. Luke's Medical Center. "Early Drug Therapy For Recently Infected HIV Patients." ScienceDaily. www.sciencedaily.com/releases/2001/09/010913074042.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins